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Association of SLC1A2 and SLC17A7 
polymorphisms with major depressive 
disorder in a Thai population
Benjamard Thaweethee1,2, Sirijit Suttajit3, Samur Thanoi1,2, Caroline F. Dalton4, Gavin P. Reynolds2,4, 
Sutisa Nudmamud-Thanoi1,2,*
Abstract
Background: Major depressive disorder (MDD) is a common psychiatric disorder with high prevalence and high risk 
of suicide. Genetic variation of glutamate transporters may associate with MDD and suicide attempt.
Objectives: To evaluate polymorphisms of excitatory amino acid transporter 2 gene (SLC1A2; rs752949, rs1885343, 
rs4755404, and rs4354668) and vesicular glutamate transporter 1 gene (SLC17A7; rs1043558, rs2946848, and 
rs11669017) in patients with MDD with and without suicide attempt, and determine the association of these 
polymorphisms with age of onset and severity of MDD.
Methods: DNA was extracted from blood taken from patients with MDD (n = 100; including nonsuicidal [n = 50] 
and suicidal [n = 50] subgroups) and controls (n = 100). Genotyping was conducted using TaqMan single-nucleotide 
polymorphism (SNP) genotyping.
Results: We found a significant difference in SLC17A7 rs2946848 genotype distribution between patients in the MDD 
and control groups (P = 0.016). Moreover, significant differences in SLC1A2 rs752949 (P = 0.022) and SLC17A7 
rs2946848 (P = 0.026) genotype distributions were observed between patients in the nonsuicidal MDD and suicidal 
MDD groups. SLC1A2 rs1885343 A allele carriers showed significantly lower age of onset than GG genotype 
(P = 0.049). Furthermore, the severity of MDD indicated by the Hamilton Depression Rating Scale (HDRS) score of G 
allele carriers of SLC1A2 rs4755404 was significantly greater than the CC genotype (P = 0.013).
Conclusions: Polymorphisms of SLC1A2 and SLC17A7 may contribute to the risk of MDD and/or suicide attempt. An 
association of an SLC1A2 polymorphism with the severity of MDD was apparent.
Keywords: excitatory amino acid transporter 2, gene; major depressive disorder; single-nucleotide polymorphisms; SLC1A2; 
SLC17A7; suicide, attempted; vesicular glutamate transporter 1
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Major depressive disorder (MDD) or major depression is a 
common psychiatric disorder in the general population [1]. 
According to the World Health Organization (WHO), MDD 
affects more than 350 million people worldwide. Moreover, 
the Burden of Disease (BOD) Research Program in 2013 
revealed that a Thai population of around 1.5 million people 
Bereitgestellt von  Sheffield Hallam University | Heruntergeladen  17.10.19 09:19   UTC
132  B. Thaweethee et al.
suffered from depression [2]. Psychiatric disorders, especially 
MDD, have been strongly linked to suicide and suicide att-
empts [3–6]. A metaanalysis has found that approximately 
90% of the people who commit suicide have been diagnosed 
with a psychiatric disorder before death [7]. Moreover, the risk 
of suicide in depressed women and girls is 20-fold that of the 
general population [8]. MDD is thus considered a severe psy-
chiatric disorder.
Both attempted suicide and completed suicide are highly 
familial [9], in which completed suicide shows a higher con-
cordance in monozygotic twins (11.3%) than in dizygotic 
twins (1.8%) [10]. These findings indicate that genetic factors 
are involved in suicidal behavior. Genetic variation, especially 
single-nucleotide polymorphisms (SNPs), of the glutamatergic 
system has attracted attention in the study of psychiatric dis-
orders. Glutamate, a major excitatory neurotransmitter in the 
central nervous system, plays important roles in balancing brain 
functions and modulating various mood states. The packaging 
and release of vesicular glutamate can be influenced by stress 
and psychotropic drugs [11]. Abnormalities of glutamate con-
centrations in brain areas that involve mood and emotion have 
been recognized in patients with MDD [12–14]. Increases 
in glutamate levels in plasma and serum have been found in 
patients with MDD [15–18], in whom these increases may be 
a result of abnormalities of glutamate transporters. A postmor-
tem study has demonstrated a downregulation of expression 
of the gene for excitatory amino acid transporter 2 (EAAT2) 
(SLC1A2) in anterior cingulate cortex and dorsolateral prefron-
tal cortex of patients with MDD [19]. Moreover, a low EAAT2 
protein expression was found in the orbitofrontal cortex of 
patients with MDD [20]. Furthermore, a decreased expression 
of the gene for vesicular glutamate transporter 1 (VGLUT1) 
(SLC17A7) was found in the entorhinal cortex of patients with 
either MDD or bipolar disorder [21], and in middle temporal 
gyrus in suicide victims of severe psychiatric disorders inclu-
ding MDD, bipolar disorder, and schizophrenia [21]. By cont-
rast, increased SLC17A7 expression was observed in the anterior 
cingulate cortex of patients with schizophrenia [22]. Therefore, 
genes encoding glutamate transporters may vary in psychiatric 
diseases including MDD and warrant genetic study.
To our knowledge, there are only a few studies reporting 
genetic polymorphisms of SLC1A2 and SLC1A7 in MDD. 
Most studies have reported an association of SNPs of SLC1A2 
and SLC17A7 with schizophrenia [23–28] and bipolar disorder 
[29, 30]. A study of SLC1A2 rs4755404 has reported protec-
tive and risk genetic variants for suicide [31]. Genetic poly-
morphisms of SLC1A2 and SLC17A7 may confer vulnerability 
for MDD and suicidal behavior. Understanding the association 
between genetic polymorphisms and MDD including suicide 
may be valuable in improving its prevention, diagnosis, and 
effective treatment. Therefore, we aimed to determine the 
association of such gene polymorphisms with MDD and sui-
cidal behavior or ideation. The association of gene polymor-
phisms of SLC1A2 and SLC17A7 with the age of onset and 
severity of MDD in MDD patients was investigated.
Methods
Subjects
All experimental protocols used in the present study were appro-
ved by the Human Ethics Committee of Naresuan University 
(certificate of approval No. 524/2017) and Faculty of Medicine, 
Chiang Mai University (certificate of approval No. 314/2017). 
All participants were fully informed about the study, and docu-
mented informed consent was obtained individually from each 
participant. The participants (18–65 years old) were divided 
into 2 groups: MDD and control (n = 100 per group). MDD was 
diagnosed by a psychiatrist in the Department of Clinical Psy-
chiatry, Maharaj Nakorn Chiang Mai Hospital, Thailand, based 
on criteria in the Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition (DSM-5). The Hamilton Depression 
Rating Scale (Thai version; Thai HDRS-17) was used to indi-
cate depression. Patients who had a history of schizophrenia, 
bipolar disorder, or drug addiction were excluded from the 
present study. The participants in the MDD group were divided 
into 2 subgroups (n = 50 per subgroup) including patients with 
MDD without suicide attempt (nonsuicidal MDD group) and 
those with suicide attempt (suicidal MDD group) according to 
the Mini International Neuropsychiatric Interview (MINI; Thai 
version 5.0.0—revised 2007). The duration of illness, the period 
that patients suffered depressive symptoms before diagnosis of 
MDD, and age of onset were also recorded. The control group 
included healthy volunteer participants who had no previous 
history of schizophrenia, mood disorder, anxiety, or drug addic-
tion. The age and sex of the control participants were matched 
with those of the patients with MDD. The mental health of the 
participants in the control group was evaluated using the Thai 
Mental Health Indicator (TMHI-66). Participants who identi-
fied with abnormal mental health were excluded from the study.
Blood sample collection and DNA extraction
Fingertip blood samples were dropped on Whatman Flin-
ders Technology Associations (FTA) cards (GE Healthcare) 
and allowed to dry completely at room temperature. Dried 
blood samples were kept at room temperature following the 
manufacturer’s instructions until used. The blood samples 
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were collected over approximately 6 months. Following the 
instruction manual for the FTA cards, genomic DNA stored on 
FTA cards at room temperature for over 17 years has been suc-
cessfully amplified by polymerase chain reaction (PCR). Dried 
blood spots were punched using a Harris Micro Punch 2.0 mm 
(GE Healthcare), and then DNA was extracted using Chelex 
100 resin (Bio-Rad). Briefly, FTA disks were washed 3 times 
in 1 mL high purify water at room temperature for 10 min with 
occasional inversion. After discarding all liquid, FTA disks 
were incubated in 5% Chelex 100 resin at 56°C for 20 min 
and mixed by vortexing. FTA disks were further incubated 
at 100°C for 8 min and centrifuged at 20,000 ×g for 3 min. 
Supernatant containing DNA was carefully collected into a 
new tube and kept at –80°C until use. The DNA concentration 
was measured using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific) according to the manufacturer’s protocol.
SNP study
SNPs of SLC1A2 including rs752949, rs1885343, rs4755404, 
and rs4354668 and SNPs of SLC17A7 including rs1043558, 
rs2946848, and rs11669017 were selected following previ-
ous reports in association with psychiatric disorders. From 
LDlink calculation, rs752949 has high linkage disequilibrium 
with rs1885343 (Dʹ = 0.93 in Chinese Dai in Xishuangbanna, 
China), in which a role for EAAT2 protein expression in the 
nucleus accumbens was reported [32]. Previous studies have 
reported an association of rs4755404 with schizophrenia [23] 
and suicide [31]. rs4354668 is supposed to play important 
roles in patients with schizophrenia [24] and bipolar disorder 
[25, 29]. A trend towards the association of rs1043558 with 
schizophrenia has been found in psychiatric patients [28]. Alt-
hough the functional roles of rs2946848 and rs11669017 have 
not been reported to our knowledge, rs2946848 located at the 
promoter region and rs11669017 located near the 5ʹ position 
might be involved with transcription factor binding sites. SNP 
information was collected from the SNP database (dbSNP; 
https://www.ncbi.nlm.nih.gov/snp/) and the Ensembl project 
(http://www.ensembl.org/index.html).
Each SNP genotyping was examined separately using a 
TaqMan SNP genotyping real-time PCR. PCR reactions were 
conducted in a total volume of 10 mL containing 10 ng of DNA 
template, 1× TaqMan GTXpress Master Mix (Thermo Fisher 
Scientific), nuclease-free water, and 1× predesigned TaqMan 
SNP Genotyping Assays (Assay ID: C___605534_20 for 
rs752949, C___1292328_10 for rs1885343, C__27982507_10 
for rs4755404, C__27142767_10 for rs4354668, 
C___9493385_10 for rs1043558, C__11494903_10 for 
rs2946848, and C__27843812_10 for rs11669017; Thermo 
Fisher Scientific). PCR amplification was conducted for 
40 cycles with PCR conditions comprising pre-PCR read 
stage at 60°C for 30 s, DNA polymerase activation at 95°C 
for 10 min, denaturation at 95°C for 15 s, annealing/exten-
sion at 60°C for 1 min, and post-PCR read stage at 60°C for 
30 s with StepOnePlus and QuantStudio 3 Real-Time PCR 
Systems (Applied Biosystems). Subsequently, the genotypes 
were determined and clustered using StepOne Software or 
QuantStudio Software (Applied Biosystems).
Statistical analysis
The Statistical Package for the Social Sciences (SPSS Statis-
tics for Windows; version 17.0) was used to perform a Pearson 
χ2 test to analyze differences in sex and genotype frequency 
between the 2 groups. Univariate analysis of variance and an 
independent samples t test were used to analyze differences 
in age, age of onset, duration of illness, and HDRS score fre-
quency between the 2 groups. A Hardy–Weinberg equilibrium 
test was conducted using PLINK software (version 1.07). Dif-
ferences with P < 0.05 in tests of statistical inference were 
considered significant.
Results
The demographic data of participants showed no significant 
difference of age and sex between those in the MDD and 
control groups (P > 0.05). The duration of illness in patients in 
the suicidal MDD group was significantly longer than that in 
patients in the nonsuicidal MDD group (P = 0.024), while age, 
sex, age of onset, and HDRS scores were not significantly dif-
ferent between the groups (P > 0.05; Table 1). Female patients 
with MDD had significantly higher HDRS scores than male 
patients with MDD (P = 0.004; Table 1).
All SNPs of SLC1A2 and SLC17A7 in the control group 
were in Hardy–Weinberg equilibrium (P > 0.05; data not 
shown). The significant values of genotype distribution in 
the comparison of common homozygous to minor allele car-
riers (dominant model) between patients in the MDD group 
and volunteers in the control groups, and between patients in 
the nonsuicidal MDD and suicidal MDD groups were stron-
ger than the 3 genotype comparisons (additive model), and 
these results are then used in further analysis. The distribu-
tion of genotype frequencies of SLC17A7 rs2946848 was sig-
nificantly different between patients in the MDD group and 
volunteers in the control group (P = 0.016), in which the C 
allele carrier (CC/CT genotype) was more common in patients 
in the MDD group (Table 2).
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Moreover, the distribution of genotype frequencies of 
SLC1A2 rs752949 and SLC17A7 rs2946848 was significantly 
different between patients in the nonsuicidal MDD and suici-
dal MDD groups (P = 0.022 and P = 0.026, respectively) in 
which the T allele carrier (TT/CT genotype) of rs752949 and 
TT genotype of SLC17A7 rs2946848 were more common in 
patients in the suicidal MDD group. We did not find any signi-
ficantly different genetic distributions of SLC1A2 rs1885343, 
SLC1A2 rs4755404, SLC1A2 rs4354668, SLC17A7 
rs1043558, and SLC17A7 rs11669017 between patients in the 
MDD group and volunteers in the control group, or between 
patients in the nonsuicidal MDD and suicidal MDD groups 
(Table 2).
The association study of gene polymorphisms with age of 
onset and HDRS scores in patients with MDD demonstrated 
that A allele carriers (AA/AG genotype) of SLC1A2 rs1885343 
had a significantly lower age of onset than patients with 
MDD who were GG homozygotes (P = 0.049; Figure 1A) 
(33.80 ± 14.36 and 40.09 ± 16.23, respectively). Moreover, 
the HDRS scores of patients with MDD who were G allele 
carriers (GG/CG genotype) of SLC1A2 rs4755404 were signi-
ficantly lower than those of patients with MDD and a common 
CC genotype (P = 0.013; Figure 1B; 11.37 ± 6.94 and 
15.37 ± 7.84, respectively). We found no significant associ-
ation of SLC1A2 rs752949, SLC1A2 rs4354668, SLC17A7 
rs1043558, SLC17A7 rs2946848, and SLC17A7 rs11669017 
with either age of onset or HDRS scores. Nor did we find any 
significant association of the duration of illness with SNPs.
Table 1. Demographic data and clinical characteristics of the participants in the present study











Age (years), 44.31 ± 14.77 43.74 ± 15.00 0.79† 44.38 ± 15.32 44.24 ± 14.35 0.96†
Sex
Female 74 (74) 75 (75) 0.94† 39 (78) 35 (70) 0.36†
Male 26 (26) 25 (25) 11 (22) 15 (30)
Age of onset (years old) 38.34 ± 16.28 33.66 ± 13.93 0.12†
















†MDD group vs. control group or nonsuicidal MDD group vs. suicidal MDD group
‡Female MDD patients vs. male MDD patients
*P < 0.05 
HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder
Discussion
In the present study, we found an association of SLC17A7 
rs2946848 with MDD. We showed that C allele carriers (CC/
CT) of SLC17A7 rs2946848 were more common among MDD 
patients. According to the MatInspector software analysis, 
the SNP rs2946848 is in intron 2 and is predicted to locate in 
the promoter region of SLC17A7. This SNP might interrupt 
mRNA transcription of SLC17A7 leading to a glutamate trans-
porter abnormality in those with MDD. Our findings are con-
sistent with those of other studies that have found differential 
changes in SLC17A7 expression in bipolar disorder [21] and 
schizophrenia [22].
The function of SNPs of glutamate transporter-related 
genes in those with MDD is unclear. The present study found 
an association of SLC1A2 rs752949 and SLC17A7 rs2946848 
with suicide attempt in patients with MDD. Bearing a T allele 
(TT/CT) of SLC1A2 rs752949 and TT genotype of SLC17A7 
rs2946848 may be risk factors for suicide attempt in those 
with MDD. To our knowledge, the associations of these 
2 SNPs with MDD or other psychiatric disorders have not been 
reported previously. Here we report evidence of an association 
of SLC1A2 rs752949 and SLC17A7 rs2946848 with MDD.
We found that the duration of illness in patients with MDD 
and suicidal attempt is longer than that in patients with MDD 
who did not attempt suicide (nonsuicidal MDD group). Our 
findings are consistent with a previous study that found a cor-
relation between suicidal symptoms and the duration of illness 
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Table 2. Genotype frequencies of SLC1A2 and SLC17A7 polymorphisms in the control and MDD groups
n Genotype (frequency) †P ‡P
SLC1A2 rs752949 CC CT TT
Control 100 74 (0.74) 26 (0.26) 0 (0.00) 0.25 0.23
MDD 100 81 (0.81) 18 (0.18) 1 (0.01)
Nonsuicidal 50 45 (0.90) 4 (0.08) 1 (0.02) 0.023* 0.022*
Suicidal 50 36 (0.72) 14 (0.28) 0 (0.00)
SLC1A2 rs1885343 AA AG GG
Control 100 17 (0.17) 51 (0.51) 32 (0.32) 0.16 0.65
MDD 100 26 (0.26) 39 (0.39) 35 (0.35)
Nonsuicidal 50 14 (0.28) 17 (0.34) 19 (0.38) 0.59 0.53
Suicidal 50 12 (0.24) 22 (0.44) 16 (0.32)
SLC1A2 rs4755404 CC CG GG
Control 100 33 (0.33) 45 (0.45) 22 (0.22) 0.89 0.65
MDD 100 30 (0.30) 46 (0.46) 24 (0.24)
Nonsuicidal 50 12 (0.24) 27 (0.54) 11 (0.22) 0.25 0.19
Suicidal 50 18 (0.36) 19 (0.38) 13 (0.26)
SLC1A2 rs4354668 GG GT TT
Control 100 46 (0.46) 47 (0.47) 7 (0.07) 0.52 0.32
MDD 100 53 (0.53) 39 (0.39) 8 (0.08)
Nonsuicidal 50 27 (0.54) 21 (0.42) 2 (0.04) 0.39 0.84
Suicidal 50 26 (0.52) 18 (0.36) 6 (0.12)
SLC17A7 rs1043558 GG GT TT
Control 100 25 (0.25) 55 (0.55) 20 (0.20) 0.85 0.74
MDD 100 23 (0.23) 59 (0.59) 18 (0.18)
Nonsuicidal 50 9 (0.18) 32 (0.64) 9 (0.18) 0.47 0.24
Suicidal 50 14 (0.28) 27 (0.54) 9 (0.18)
SLC17A7 rs2946848 CC CT TT
Control 100 4 (0.04) 36 (0.36) 60 (0.60) 0.047* 0.016*
MDD 100 8 (0.08) 49 (0.49) 43 (0.43)
Nonsuicidal 50 3 (0.06) 31 (0.62) 16 (0.32) 0.034* 0.026*
Suicidal 50 5 (0.10) 18 (0.36) 27 (0.54)
SLC17A7 rs11669017 CC CG GG
Control 100 24 (0.24) 49 (0.49) 27 (0.27) 0.69 0.87
MDD 100 19 (0.19) 53 (0.53) 28 (0.28)
Nonsuicidal 50 14 (0.28) 23 (0.46) 13 (0.26) 0.07 0.66
Suicidal 50 5 (0.10) 30 (0.60) 15 (0.30)
†MDD group vs. control group or nonsuicidal-MDD group vs. suicidal-MDD group
‡Analysis with common homozygotes vs. minor allele carriers
*P < 0.05 
MDD, major depressive disorder
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in patients with MDD [33]. Degeneration of brain, in which 
decreased hippocampal volume is correlated with the dura-
tion of depression has been reported for patients with MDD 
[34–36]. Moreover, patients with MDD who have attempted 
suicide were found to have smaller hippocampal volume than 
those patients with MDD who had not attempted suicide [37]. 
These findings suggest that the depression might somehow 
progressively reduce hippocampal volume with consequent 
abnormalities in brain function, which may be reflected by 
psychiatric symptoms.
We found an association of SLC1A2 rs1885343 with the 
age of MDD onset in patients we studied. Those with a GG 
genotype of SLC1A2 rs1885343 showed a significantly greater 
age of MDD onset than those patients who were A allele car-
riers (AA/AG genotype). SNP rs1885343 is located at intron 1 
of SLC1A2, where it may have a functional effect on EAAT2 
expression. Supporting this effect of SLC1A2 rs1885343, our 
previous study reported an influence of rs1885343 on EAAT2 
expression in the nucleus accumbens of healthy volunteers 
in whom those with the GG genotype showed lower expres-
sion of EAAT2 than those who were A allele carriers (AA/
AG) [32]. Therefore, SLC1A2 rs1885343 might contribute to 
changes of EAAT2 expression in people with MDD, as con-
sistent with previous reports of reduced cortical expression of 
SLC1A2 and EAAT2 in those with MDD [19, 20].
As consistent with a previous report [8], we found that 
symptom severity in patients with MDD is positively cor-
related with sex in women and girls who have greater risk 
than men and boys. Moreover, the present study found that 
SLC1A2 rs4755404 was associated with symptom severity in 
patients with MDD. The CC genotype of this SNP showed 
higher HDRS scores. The CC genotype may also influence 
gene expression because in patients with schizophrenia it is 
associated with a significant increase in the EAAT2 exon 9 
skipping splice variant mRNA expression in the anterior cin-
gulate cortex pyramidal cells compared with that in those with 
a G genotype [26].
This preliminary study is limited by its small sample size. 
Moreover, although a Bonferroni correction has been made for 
multiple testing, only SLC17A7 rs2946848 showed a signifi-
cant association with MDD. Therefore, a further study in a 
substantially larger sample size determined by a power analy-
sis is needed to confirm the gene polymorphism associations 
with MDD and suicide.
Conclusions
This study provides initial evidence for SLC1A2 and SLC17A7 
polymorphisms as risk factors for MDD and/or suicide 
attempt. Moreover, an association of SLC1A2 polymorphism 
with the severity of MDD is suggested. These possible risk 
factors may be predictive markers for diagnosis and helpful in 
development of an effective treatment.
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Figure 1. Association of gene polymorphisms with age of onset and HDRS scores in MDD patients. (A) Age of onset (years) of common GG homo-
zygotes and A allele carriers (AA/AG genotype) of SLC1A2 rs1885343 and (B) HDRS scores of common CC homozygotes and G allele carriers (GG/CG 
genotype) of SLC1A2 rs4755404 in MDD patients (n = 100). Bars with black or white fill represent mean data, error bars SEM. *P < 0.05; independent 
samples t test.  
HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder; SEM, standard error of the mean
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